Key facts
- Innerva Pharmaceuticals’s last known valuation is $940K (Feb 2025).
- It has raised $2.8M; the latest was Seed Round ($470K) in Feb 2025.
- Notable investors include Inveready Asset Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Innerva Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Innerva Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innerva Pharmaceuticals
Operator of an ophthalmic pharmaceutical firm intended for the research and development of new medications for the treatment of ocular pain that accompanies various diseases. The company is developing a novel treatment for ocular pain associated with dry eye and other diseases of the ocular surface, enabling doctors to provide medications.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 4
- Website
- innervapharma.com/
- Ownership
- Privately Held (backing)
Innerva Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innerva Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innerva Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.